1-7 of 7
Minh Dinh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Catherine Thieblemont, Yasmin H. Karimi, Chan Y Cheah, Michael Roost Clausen, Kim Linton, Tycel J. Phillips, Franck Morschhauser, Martin Hutchings, Rebekah Conlon, Saurabh Mukhopadhyay, Aurelie Le Maitre, Yu Deng, Mariana Sacchi, Thomas Doerr, Minh Dinh, William Palo, Loretta Nastoupil
Journal: Blood
Blood (2024) 144 (Supplement 1): 4491.
https://doi.org/10.1182/blood-2024-200957
Published: 2024
Journal Articles

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Julie M. Vose, Tatyana Feldman, Martine E.D. Chamuleau, Won Seog Kim, Pieternella Lugtenburg, Tae Min Kim, Pau Abrisqueta Costa, Chan Y. Cheah, Ingrid Cecilia Glimelius, Brian Hess, Wojciech Jurczak, Gerardo Musuraca, Adam J. Olszewski, Minh Dinh, Nurgul Kilavuz, Monica Wielgos-Bonvallet, Tommy Li, Zhu Li, Christian Eskelund, Umar Farooq
Journal: Blood
Blood (2023) 142 (Supplement 1): 1729.
https://doi.org/10.1182/blood-2023-180333
Published: 2023
Journal Articles

Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5

Irit Avivi Mazza, Won Seog Kim, Po-Shen Ko, Carlos Grande, David Lavie, David Chism, Mostafa Seliem, Edwin E. Jeng, Neha Joshi, Satya Siddani, Wissam Assaily, Mariana Sacchi, Minh Dinh, Abraham Avigdor
Journal: Blood
Blood (2023) 142 (Supplement 1): 438.
https://doi.org/10.1182/blood-2023-180089
Published: 2023
Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Lorenzo Falchi, Lori A. Leslie, David Belada, Katerina Kopeckova, Fritz Offner, Joshua Brody, Miguel Canales, Alejandro Martín García-Sancho, Marcel Nijland, P-O Andersson, Farrukh T. Awan, Jacob Haaber Christensen, Kristina Drott, Mats Hellström, Catharina Lewerin, Mayur Narkhede, Sylvia Snauwaert, Björn E Wahlin, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, Joost S.P. Vermaat, Pau Abrisqueta
Journal: Blood
Blood (2022) 140 (Supplement 1): 1471–1473.
https://doi.org/10.1182/blood-2022-158232
Published: 2022
Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Lorenzo Falchi, Pau Abrisqueta, Marcel Nijland, Sirpa Leppä, Martin Hutchings, Harald Holte, Reid W Merryman, Pieternella Lugtenburg, Sven de Vos, Chan Y. Cheah, Jacob Haaber Christensen, Luca Arcaini, Kristina Drott, Mats Hellström, Lori A. Leslie, Umberto Vitolo, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, David Belada
Journal: Blood
Blood (2022) 140 (Supplement 1): 1464–1466.
https://doi.org/10.1182/blood-2022-158203
Published: 2022
Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik
Journal: Blood
Blood (2022) 140 (Supplement 1): 12108–12109.
https://doi.org/10.1182/blood-2022-157596
Published: 2022
Journal Articles

Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R 2 ) Vs R 2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Lorenzo Falchi, Franck Morschhauser, John G. Gribben, Huiqiang Huang, Minh Dinh, Rebekah Conlon, Xiaorong Chen, Brian Elliot, John F. Seymour
Journal: Blood
Blood (2022) 140 (Supplement 1): 9338–9339.
https://doi.org/10.1182/blood-2022-157584
Published: 2022